Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Globe Life Rides On Rising Premiums, Solid Capital Position

Published 03/02/2020, 08:23 PM
Updated 07/09/2023, 06:31 AM

Globe Life Inc. (NYSE:GL) is well-poised for growth, benefitting from higher premium revenues from its life and health businesses along with a robust capital position.

The company has a decent surprise history. It surpassed estimates in three of the trailing four quarters, with a beat of 1.2%, on average. In the past year, its shares have gained 16.6% against the industry’s decline of 6.4%.

What’s Driving Globe Life?

The company continues to perform well on strong performance of its two revenue components — life premium and health premium. Life premium, which contributes a significant portion to Globe Life’s revenues, moved up 4.6% year over year in 2019. The upside can be attributed to consistent performance at one of its most important distribution channels — American Income Exclusive Agency.

The company also seems to witness a substantial improvement in health premiums. In 2019, health premiums increased 6.1% from the prior year. The improvement mainly came on the back of strong performance in Globe Life’s United American Independent distribution channel.

The company has a long history of returning capital to shareholders. It has been actively increasing shareholders’ wealth through an ongoing buyback program since initiating it in 1986.

Globe Life has also been generating free cash flow consistently. Riding on solid cash flow, the company engages in share buybacks. However, rise in administrative expenses due to increased pension costs is a significant headwind for Globe Life.

Zacks Rank & Stocks to Consider

Globe Life currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the same space are PRA Group, Inc. (NASDAQ:PRAA) , Houlihan Lokey, Inc. (NYSE:HLI) and Moody's Corporation (NYSE:MCO) . While PRA Group currently sports a Zacks Rank #1 (Strong Buy), Houlihan and Moody’s carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

All three companies surpassed estimates in the last reported quarters by 20%, 18.92% and 4.17%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Moody's Corporation (MCO): Free Stock Analysis Report

PRA Group, Inc. (PRAA): Free Stock Analysis Report

Houlihan Lokey, Inc. (HLI): Free Stock Analysis Report

Globe Life Inc. (GL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.